Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee

Zainab Shahid, Aaron M. Etra, John E. Levine, Marcie L. Riches, Aliyah Baluch, Joshua A. Hill, Ryo Nakamura, Amir A. Toor, Celalettin Ustun, Jo Anne H. Young, Miguel Angel Perales, David J. Epstein, Hemant S. Murthy

Research output: Contribution to journalArticlepeer-review

Abstract

The Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) was established in 2001 to conduct large multi-institutional clinical trials addressing important issues towards improving the outcomes of HCT and other cellular therapies. Trials conducted by the network investigating new advances in HCT and cellular therapy not only assess efficacy but require careful capturing and severity assessment of adverse events and toxicities. Adverse infectious events in cancer clinical trials are typically graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE). However, there are limitations to this framework as it relates to HCT given the associated immunodeficiency and delayed immune reconstitution. The BMT-CTN Infection Grading System is a monitoring tool developed by the BMT CTN to capture and monitor infectious complications and differs from the CTCAE by its classification of infections based on their potential impact on morbidity and mortality for HCT recipients. Here we offer a report from the BMT CTN Infectious Disease Technical Committee regarding the rationale, development, and revising of BMT-CTN Infection Grading System and future directions as it applies to future clinical trials involving HCT and cellular therapy recipients.

Original languageEnglish
Pages (from-to)540.e1-540.e13
JournalTransplantation and Cellular Therapy
Volume30
Issue number5
DOIs
StatePublished - May 2024

Keywords

  • Clinical Trials
  • Grading
  • Hematopoietic Cell Transplantation
  • Infection

Fingerprint

Dive into the research topics of 'Defining and Grading Infections in Clinical Trials Involving Hematopoietic Cell Transplantation: A Report From the BMT CTN Infectious Disease Technical Committee'. Together they form a unique fingerprint.

Cite this